The most significantly enriched pathway was “hsa05200:Pathways in cancer” with 15 target proteins (HSP90AA1, NOS2, GSTP1, IGF1, MMP9, EGFR, IGF1R, RXRB, AKT2, KIT, ABL1, RARA, AKT1, RARB, FGFR1), followed by “hsa05205:Proteoglycans in cancer” with 12 target genes (ERBB4, PDPK1, SRC, AKT2, KDR, AKT1, IGF1, ESR1, MMP9, EGFR, FGFR1, IGF1R). This evidence concerns the gene RARA and cancer.